Natalizumab Biosimilar - Research Grade

In stock
Only %1 left
SKU
ICH4037
Add to Compare
$120.00
Add to Wish List

Bulk Natalizumab Biosimilar - Research Grade

Product Benefits:

ichorbio's Natalizumab Biosimilar - Research Grade is manufactured in a cGMP compliant facility.

Size:

ichorbio's research grade natalizumab biosimilar is available in the following sizes: 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of our natalizumab biosimilar - research grade. Please contact us for pricing.

Target:

α4β1 integrin

Clone:

n/a

Isotype:

Human IgG4

Other Names:

alpha-4 integrin

Host:

CHO Cells

Species Reactivity:

Human

Specificity:

Detects human α4β1 integrin.

Purification Method:

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

Natalizumab biosimilar - research grade is a humanized monoclonal antibody that blocks α4β1 integrin. It is an IgG1 kappa immunoglobulin with an approximate molecular weight of 149 kDa.

Concentration:

1.0 - 5.0 mg/ml

Formulation:

Sterile, preservative-free, buffer includes sodium chloride; sodium phosphate, monobasic, monohydrate; sodium phosphate, dibasic, heptahydrate; polysorbate 80, pH 6.1. BSA and Azide free.

Purity:

>98% by SDS-PAGE and HPLC

Endotoxin:

≤ 1.0 EU/mg as determined by the LAL method

Storage:

Natalizumab is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:

Functional Assays

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Isotype Control:

Bulk Human IgG4 Isotype Control (IB4) [ICH2257]

Use: ichorbio's natalizumab biosimilar is for research use only (RUO).
More Information
Concentration 9.73mg/ml
isotype Human IgG4
Host CHO Cells
Write Your Own Review
You're reviewing:Natalizumab Biosimilar - Research Grade
Your Rating
Back to Top